[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE066311T2 - Rekombináns nukleinsav-konstrukció - Google Patents

Rekombináns nukleinsav-konstrukció

Info

Publication number
HUE066311T2
HUE066311T2 HUE19749727A HUE19749727A HUE066311T2 HU E066311 T2 HUE066311 T2 HU E066311T2 HU E19749727 A HUE19749727 A HU E19749727A HU E19749727 A HUE19749727 A HU E19749727A HU E066311 T2 HUE066311 T2 HU E066311T2
Authority
HU
Hungary
Prior art keywords
nucleic acid
acid construct
recombinant nucleic
recombinant
construct
Prior art date
Application number
HUE19749727A
Other languages
English (en)
Inventor
Klaus Giese
Oliver Keil
Joerg Kaufmann
Original Assignee
Pantherna Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18188489.1A external-priority patent/EP3608426A1/en
Application filed by Pantherna Therapeutics Gmbh filed Critical Pantherna Therapeutics Gmbh
Publication of HUE066311T2 publication Critical patent/HUE066311T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE19749727A 2018-08-10 2019-08-07 Rekombináns nukleinsav-konstrukció HUE066311T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18188489.1A EP3608426A1 (en) 2018-08-10 2018-08-10 Recombinant nucleic acid construct
EP18194023 2018-09-12
EP18248243 2018-12-28

Publications (1)

Publication Number Publication Date
HUE066311T2 true HUE066311T2 (hu) 2024-07-28

Family

ID=67544260

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19749727A HUE066311T2 (hu) 2018-08-10 2019-08-07 Rekombináns nukleinsav-konstrukció

Country Status (18)

Country Link
US (1) US20210261980A1 (hu)
EP (1) EP3833786B1 (hu)
JP (1) JP2021533821A (hu)
KR (1) KR20210044240A (hu)
CN (1) CN112567053A (hu)
AU (1) AU2019319035A1 (hu)
BR (1) BR112021002333A2 (hu)
CA (1) CA3108670A1 (hu)
DK (1) DK3833786T5 (hu)
ES (1) ES2970185T3 (hu)
FI (1) FI3833786T3 (hu)
HU (1) HUE066311T2 (hu)
IL (1) IL280157A (hu)
MX (1) MX2021001547A (hu)
PL (1) PL3833786T3 (hu)
SG (1) SG11202100455WA (hu)
WO (1) WO2020030672A1 (hu)
ZA (1) ZA202100242B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
WO2022106072A1 (en) 2020-11-18 2022-05-27 Aplicacion Y Suministros Textiles, S.A.U. Textile stone washing process
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100941A2 (en) * 1998-07-27 2001-05-23 Valentis Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
GB9905498D0 (en) * 1999-03-11 1999-05-05 Glaxo Group Ltd Expression
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2010146584A1 (en) * 2009-06-15 2010-12-23 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US11149254B2 (en) * 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
DE202015010000U1 (de) * 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
US20190298657A1 (en) * 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
EP3558354A1 (en) * 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine

Also Published As

Publication number Publication date
BR112021002333A2 (pt) 2021-05-04
EP3833786B1 (en) 2023-12-27
ZA202100242B (en) 2022-05-25
PL3833786T3 (pl) 2024-05-06
DK3833786T3 (da) 2024-03-04
CN112567053A (zh) 2021-03-26
EP3833786A1 (en) 2021-06-16
CA3108670A1 (en) 2020-02-13
FI3833786T3 (fi) 2024-03-15
AU2019319035A1 (en) 2021-02-04
KR20210044240A (ko) 2021-04-22
MX2021001547A (es) 2021-06-23
SG11202100455WA (en) 2021-02-25
WO2020030672A1 (en) 2020-02-13
US20210261980A1 (en) 2021-08-26
JP2021533821A (ja) 2021-12-09
IL280157A (en) 2021-03-01
ES2970185T3 (es) 2024-05-27
DK3833786T5 (da) 2024-08-19

Similar Documents

Publication Publication Date Title
SG11202104136YA (en) Heterodimeric fc-fused proteins
IL254000A0 (en) Nucleic acid sequence composition
GB201507119D0 (en) Nucleic Acid Construct
GB201507115D0 (en) Nucleic Acid Construct
GB201507111D0 (en) Nucleic acid construct
GB201507108D0 (en) Nucleic acid construct
GB201507104D0 (en) Nucleic acid construct
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
GB201608197D0 (en) Novel proteins
ZA202006252B (en) Yeast proteins
GB201705484D0 (en) Genetic construct
ZA202100242B (en) Recombinant nucleic acid construct
PL3630961T3 (pl) Konstrukt genetyczny
GB201812474D0 (en) Nucleic acid construct
GB201600512D0 (en) Recombinant protein production
GB201818816D0 (en) Regulatory nucleic acid sequences
GB201913898D0 (en) Nucleic acid construct
EP3766972A4 (en) NUCLEIC ACID COMPLEX
PT3833786T (pt) Construção de ácido nucleico recombinante
GB201911522D0 (en) Genetic construct
GB201810052D0 (en) Polypeptide
IL253305A0 (en) Improved proteins for bone growth
GB201819021D0 (en) Genetic construct
GB201815836D0 (en) Nucleic acid conjugates
GB201909710D0 (en) Proteins